United States: FDA Releases Draft Guidance On Section 503B Fees For Drug Compounding Outsourcing Facilities; Details Process For Paying And Calculating Fees

On April 1, 2014, the U.S. Food and Drug Administration (FDA) published notice of its Draft Guidance for Industry on Fees for Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and Cosmetic Act ("Draft Guidance"), which sets forth FDA's current thinking on the annual establishment and reinspection fees under Section 503B, as well as the procedures for submitting fees, for annual fee adjustments and for establishing entitlement to the small business fee reduction.

As detailed in an earlier Duane Morris Alert, Section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) creates a new FDA-regulated entity called an "outsourcing facility," which is permitted to compound sterile drugs for human use with or without a prescription. Outsourcing facilities are required to register with FDA, comply with Current Good Manufacturing Practices (cGMPs), report adverse events to FDA and make semiannual reports to FDA of the drugs the facility compounds. Outsourcing facilities are also subject to FDA inspections on a risk-based schedule and are required to pay an annual establishment fee, as well as fees for reinspection.

In its Draft Guidance, FDA notes its current thinking on the parameters of calculating these various fees under Section 503B and the procedures for paying them.

Annual Establishment Fee

  • General. Starting in 2015, outsourcing facilities must pay an annual establishment fee and will not be considered registered as an outsourcing facility until the fee is paid. The annual registration for Section 503B facilities will start on October 1 and end on December 31 of the year preceding registration (e.g., fees for 2015 will be paid October 1, 2014, through December 31, 2014). Entities that register as outsourcing facilities prior to October 1, 2014, are not required to pay an annual establishment fee for 2014, but they will be required to pay the 2015 annual fee by December 31, 2014.
  • Procedure. In the Draft Guidance, FDA states that it expects to invoice the annual establishment fee no later than three business days after a facility submits its registration information. Entities should submit their registration information no later than December 10 to ensure that FDA is given sufficient time to review and invoice fees before the end of the registration period.
  • Calculating the Annual Establishment Fee. The annual establishment fee is calculated as $15,000, multiplied by an inflation adjustment factor, plus a small business adjustment factor. The full annual establishment fee must be paid regardless of when an entity registers as an outsourcing facility. For example, if a facility registers in May, which is outside of the October 1 to December 31 registration period, the full establishment fee will still be incurred.
  • Adjustment Factors. An outsourcing facility's annual establishment fee is subject to several adjustments.

    • First, Section 503B requires the annual establishment fee to be adjusted on an annual basis for inflation, which is then compounded every year.1 This is referred to as the inflation adjustment factor.
    • Second, the annual establishment fee may be adjusted for small businesses, referred to as the small business reduction. Facilities that qualify for the small business reduction are required to pay an annual establishment fee of only $5,000 multiplied by the inflation adjustment factor. In order to qualify for the small business reduction, a facility must have $1,000,000 or less in gross annual sales in the 12 months ending on April 1 of the fiscal year immediately preceding the year in which the annual establishment fee is assessed. Under Section 503B, "gross annual sales" means "total worldwide gross annual sales, in United States dollars ... including the sales of all domestic and foreign affiliates of the outsourcing facility."2 Requests for the small business reduction must be made by April 30 of the year preceding the fiscal year for the applicable fee and must be resubmitted on an annual basis.
    • Third, entities that do not qualify for the small business reduction will find their annual establishment fees increased by a small business adjustment factor, which is the total amount lost from each "small business" outsourcing facility, divided by the total number of outsourcing facilities that are not granted a small business reduction. In other words, FDA will recoup the loss from small business reductions from outsourcing facilities that are not eligible for that reduction.

Reinspection Fee

Outsourcing facilities may also be subject to reinspection fees if FDA is required to reinspect the facility. A reinspection is defined as:

[O]ne or more inspections conducted under section 704 subsequent to an inspection conducted under such provision which identified noncompliance materially related to an applicable requirement of this Act, specifically to determine whether compliance has been achieved to [FDA's] satisfaction.

In other words, FDA will charge facilities a fee if it has to visit the facility more than once because of noncompliance identified during prior inspections. The reinspection fee is $15,000 multiplied by the inflation adjustment factor and will be invoiced after the reinspection. Small businesses are not entitled to a reduced reinspection fee and will be charged the full inflation-adjusted reinspection fee. Reinspection fees that are not paid within 30 days will accrue interest and fees until the fee is paid in full.

Effect of Failure to Pay Fees

Failing to pay required fees under Section 503B can have substantially adverse effects on outsourcing facilities. For example, drugs compounded in an outsourcing facility that has not paid the required annual establishment fee are not eligible for the Section 503B exemptions to the New Drug Approval (NDA) process or the adequate directions for use labeling requirements. Moreover, drugs compounded by a facility that has not paid required fees are deemed misbranded and may not be distributed in interstate commerce. Failure to pay the annual establishment fee also means that a facility is not considered an "outsourcing" facility under Section 503B.

Dispute Resolution

If an outsourcing facility seeks to dispute the denial of a small business reduction or believes that a reinspection fee was imposed in error, the facility may request that FDA reconsider the fee. Requests for reconsideration should be made within 30 days after FDA issues its decision with respect to a fee. In the Draft Guidance, FDA recommends that reconsideration requests state the facility's basis for concluding that FDA's decision with respect to a fee was in error, and to submit additional information relevant to the facility's position. The Draft Guidance also states that FDA "expects" to rule on reconsideration requests within four months.

If a request for reconsideration is denied, facilities may then appeal FDA's reconsideration decision. Appeal requests should be made within 30 days of the reconsideration decision and should include the original FDA decision, the request for reconsideration, the reconsideration decision and the facility's arguments in support of the appeal. New information may not be presented in the appeal.

Conclusion

The Draft Guidance is the latest step taken by FDA to implement its new authority under Section 503B, and is a key guidepost for 503B entities when considering whether to apply for Section 503 status. Comments to the Draft Guidance may be submitted by June 2, 2014. FDA is accepting comments electronically at http://www.regulations.gov or in writing to the FDA Division of Dockets Management. Further details on the procedure for submitting comments to the Draft Guidance are available on the FDA's notice in the Federal Register.

If you have any questions about this Alert or would like more information, please contact Rachael G. Pontikes, Elinor L. Hart, any of the attorneys in our Pharmaceutical, Medical Device, Pharmacy & Food industry group or the attorney in the firm with whom you are regularly in contact.

Footnotes

1 Specifically, the inflation adjustment factor is added to the total fee, and the total fee from the preceding year is used to calculate the inflation adjustment factor for the current year.

2 "Affiliate" is further defined as a "business entity that has a relationship with a second business entity if, directly or indirectly—(A) one business entity controls, or has the power to control, the other business entity; or (B) a third party controls, or has power to control, both of the business entities."

This article is for general information and does not include full legal analysis of the matters presented. It should not be construed or relied upon as legal advice or legal opinion on any specific facts or circumstances. The description of the results of any specific case or transaction contained herein does not mean or suggest that similar results can or could be obtained in any other matter. Each legal matter should be considered to be unique and subject to varying results. The invitation to contact the authors or attorneys in our firm is not a solicitation to provide professional services and should not be construed as a statement as to any availability to perform legal services in any jurisdiction in which such attorney is not permitted to practice.

Duane Morris LLP, a full-service law firm with more than 700 attorneys in 24 offices in the United States and internationally, offers innovative solutions to the legal and business challenges presented by today's evolving global markets. Duane Morris LLP, a full-service law firm with more than 700 attorneys in 24 offices in the United States and internationally, offers innovative solutions to the legal and business challenges presented by today's evolving global markets. The Duane Morris Institute provides training workshops for HR professionals, in-house counsel, benefits administrators and senior managers.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions